JP2009545600A5 - - Google Patents

Download PDF

Info

Publication number
JP2009545600A5
JP2009545600A5 JP2009522882A JP2009522882A JP2009545600A5 JP 2009545600 A5 JP2009545600 A5 JP 2009545600A5 JP 2009522882 A JP2009522882 A JP 2009522882A JP 2009522882 A JP2009522882 A JP 2009522882A JP 2009545600 A5 JP2009545600 A5 JP 2009545600A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
isoindol
dione
piperidine
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009522882A
Other languages
English (en)
Japanese (ja)
Other versions
JP5465005B2 (ja
JP2009545600A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/017343 external-priority patent/WO2008019065A1/en
Publication of JP2009545600A publication Critical patent/JP2009545600A/ja
Publication of JP2009545600A5 publication Critical patent/JP2009545600A5/ja
Application granted granted Critical
Publication of JP5465005B2 publication Critical patent/JP5465005B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009522882A 2006-08-03 2007-08-02 マントル細胞リンパ腫治療のための３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンの使用 Active JP5465005B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83575206P 2006-08-03 2006-08-03
US60/835,752 2006-08-03
PCT/US2007/017343 WO2008019065A1 (en) 2006-08-03 2007-08-02 Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013168932A Division JP2013256514A (ja) 2006-08-03 2013-08-15 マントル細胞リンパ腫治療のための３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンの使用

Publications (3)

Publication Number Publication Date
JP2009545600A JP2009545600A (ja) 2009-12-24
JP2009545600A5 true JP2009545600A5 (OSRAM) 2010-09-02
JP5465005B2 JP5465005B2 (ja) 2014-04-09

Family

ID=38691762

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009522882A Active JP5465005B2 (ja) 2006-08-03 2007-08-02 マントル細胞リンパ腫治療のための３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンの使用
JP2013168932A Withdrawn JP2013256514A (ja) 2006-08-03 2013-08-15 マントル細胞リンパ腫治療のための３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013168932A Withdrawn JP2013256514A (ja) 2006-08-03 2013-08-15 マントル細胞リンパ腫治療のための３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンの使用

Country Status (26)

Country Link
US (7) US20080038263A1 (OSRAM)
EP (1) EP2046331B1 (OSRAM)
JP (2) JP5465005B2 (OSRAM)
KR (2) KR20140082859A (OSRAM)
CN (2) CN101583359B (OSRAM)
AR (1) AR062265A1 (OSRAM)
AT (1) ATE486601T1 (OSRAM)
AU (1) AU2007282027B2 (OSRAM)
CA (2) CA2836006A1 (OSRAM)
CL (1) CL2007002218A1 (OSRAM)
CY (1) CY1110989T1 (OSRAM)
DE (1) DE602007010303D1 (OSRAM)
DK (1) DK2046331T3 (OSRAM)
ES (1) ES2351069T3 (OSRAM)
HR (1) HRP20100664T1 (OSRAM)
IL (1) IL196885A (OSRAM)
ME (1) ME01937B (OSRAM)
MX (1) MX2009001268A (OSRAM)
PE (1) PE20081311A1 (OSRAM)
PL (1) PL2046331T3 (OSRAM)
PT (1) PT2046331E (OSRAM)
RS (1) RS51567B (OSRAM)
RU (1) RU2446804C2 (OSRAM)
SI (1) SI2046331T1 (OSRAM)
TW (1) TWI430797B (OSRAM)
WO (1) WO2008019065A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
WO2009114601A2 (en) * 2008-03-11 2009-09-17 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
WO2010014595A2 (en) * 2008-07-31 2010-02-04 The Ohio State University Research Foundation Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
MX2012010367A (es) * 2010-03-12 2012-11-23 Celgene Corp Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor.
RU2650636C2 (ru) 2012-05-03 2018-04-16 Янссен Сайенсиз Айрлэнд Юси Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей
CN104031122B (zh) * 2014-06-23 2016-05-11 常州市肿瘤医院 有关Cyclin D蛋白抑制剂多肽及其应用
CN104004060B (zh) * 2014-06-23 2016-04-13 重庆医科大学 Cyclin D蛋白抑制剂多肽及其应用
CN104004056B (zh) * 2014-06-23 2016-08-17 王方杰 一种关于Cyclin D蛋白抑制剂多肽及其应用
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADATION AND DEGRADATION AGENTS FOR TARGETED PROTEIN DEGRADATION
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
EP4470618A3 (en) 2019-03-06 2025-03-05 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
EA202192738A1 (ru) 2019-04-12 2022-03-17 С4 Терапьютикс, Инк. Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
WO2022032026A1 (en) 2020-08-05 2022-02-10 C4 Therapeutics, Inc. Compounds for targeted degradation of ret

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US2845770A (en) * 1956-09-26 1958-08-05 William F Fessler Baled hay rack and carrier
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3636809A (en) * 1969-07-10 1972-01-25 Nippon Musical Instruments Mfg Stringed musical instrument
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU1531492A (en) * 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) * 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5731325A (en) * 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
ATE530542T1 (de) 1996-07-24 2011-11-15 Celgene Corp Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
CA2262906C (en) * 1996-08-12 2006-10-31 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
DK1920773T3 (da) * 1996-11-05 2011-03-28 Childrens Medical Center Thalidomid og dexamethason til behandling af tumorer
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
BR9908811A (pt) * 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
ATE306469T1 (de) * 1999-03-18 2005-10-15 Celgene Corp Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
CA2319872C (en) * 2000-02-02 2012-06-19 Chun-Ying Huang Pharmaceutical composition for the treatment of hepatocellular carcinoma
SI21172A (sl) 2000-03-17 2003-10-31 Cell Therapeutics, Inc. Konjugati poliglutaminska kislina-kamptotecin in postopki za pripravo
AU2001249755A1 (en) * 2000-03-31 2001-10-15 Celgene Corporation Inhibition of cyclooxygenase-2 activity
NZ522767A (en) 2000-05-15 2004-07-30 Celgene Corp Thalidomide and a topoisomerase inhibitor for the treatment of cancer
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7812169B2 (en) 2000-11-30 2010-10-12 The Children's Medical Center Corporation Method of synthesis of 4-amino-thalidomide enantiomers
US20020128228A1 (en) * 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
ATE450529T1 (de) * 2001-02-27 2009-12-15 Governement Of The United Stat Analoga von thalidomid als angiogeneseinhibitoren
ES2325916T3 (es) * 2001-08-06 2009-09-24 The Children's Medical Center Corporation Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
CA2481387A1 (en) 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2915533B1 (en) * 2002-05-17 2017-09-13 Celgene Corporation Pharmaceutical compositions for treating cancer
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2004001004A1 (es) * 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy

Similar Documents

Publication Publication Date Title
JP2009545600A5 (OSRAM)
JP2009510171A5 (OSRAM)
RU2009107535A (ru) Применение 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-диона для лечения лимфом из клеток мантийной зоны
Zhai et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development
RU2008117432A (ru) Способы применения 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-диона для лечения определенных типов лейкоза
JP2011068653A5 (OSRAM)
JP2014040437A5 (OSRAM)
JP2016185995A5 (OSRAM)
JP2014532704A5 (OSRAM)
JP2005530784A5 (OSRAM)
NZ597830A (en) Methods and compositions for treating cancer comprising abiraterone acetate and prednisone
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
JP2011503063A5 (OSRAM)
JP2007510736A5 (OSRAM)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
AU2014325016B2 (en) Combination therapy using azabicyclo compound for cancer
JP2009539994A5 (OSRAM)
JP2011500805A5 (OSRAM)
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
JP2008533142A (ja) α７ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物
JP2009517411A5 (OSRAM)
JP2021001221A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
JP2006514681A5 (OSRAM)
JP2010504307A5 (OSRAM)
TW200640455A (en) Oral dosage form comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione